Kshivets sso2013

Cardioesophageal and
Esophageal Cancer:
Optimization of
Management
Oleg Kshivets, MD, PhD

Abstract:
Oleg Kshivets
Cardioesophageal and Esophageal Cancer:
Optimization of Management
 OBJECTIVE: Search of best treatment plan for cardioesophageal/esophageal cancer (CEC) patients
(CECP) was realized.
 METHODS: We analyzed data of 411 consecutive CECP (age=55.6±8.7 years; tumor size=6.7±3.3 cm)
radically operated (R0) and monitored in 1975-2012 (m=307, f=104; esophagogastrectomy- EG
Garlock=271, EG Lewis=140, combined EG with resection of pancreas, liver, diaphragm, colon
transversum, lung, trachea, pericardium, splenectomy=127; adenocarcinoma=216, squamous=185, mix=10;
T1=62, T2=99, T3=141, T4=109; N0=170, N1=57, M1A=184, G1=116, G2=98, G3=197; early CEC=43,
invasive=368; esophageal cancer=139, cardioesophageal cancer=272): only surgery-S=327, adjuvant
treatment-AT=84 (chemoimmunoradiotherapy=36: 5-FU+thymalin/taktivin +radiotherapy 45-50Gy,
adjuvant chemoimmunotherapy=48). Survival curves were estimated by the Kaplan-Meier method.
Differences in curves between groups of CECP were evaluated using a log-rank test. Cox modeling,
clustering, SEPATH, Monte Carlo, bootstrap simulation and neural networks computing were used to
determine any significant dependence.
RESULTS: For total of 411 CECP overall life span (LS) was 1632.2±2141.6 days, (median=783 days) and
cumulative 5-year survival (5YS) reached 40.1%, 10 years – 32.9%, 20 years – 24%. 102 CECP lived more
than 5 years without CEC progressing. 216 CECP died because of CEC during the first 5 years after
surgery. 5YS was superior significantly after AT (61.7%) compared with S (36.2%) (P=0.000 by log-rank
test). Cox modeling displayed that 5YS significantly depended on: phase transition (PT) early-invasive
CEC in term of synergetics, PT N0-N1M1A, AT, cell ratio factors (P=0.000-0.038). Neural networks
computing, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and
PT early-invasive CEC (rank=1), PT N0-N1M1A (rank=2), AT (3), segmented neutrophils/cancer cells-CC)
(4), lymphocytes/CC (5), monocytes/CC (6). Correct prediction of 5YS was 100% by neural networks
computing.
 CONCLUSIONS: Optimal management strategies for CECP are: 1) screening and early detection; 2)
availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3)
aggressive en block surgery and adequate lymphadenectomy for completeness; 4) high-precision
prediction; 5) adjuvant treatment for CECP with unfavorable prognosis.

Data:
 Males………………………………………………….307
 Females………..………………………………….......104

 Age=55.6±8.7 years
 Tumor Size=6.7±3.3 cm

 Only Surgery.………………………………………...327

 Adjuvant Chemoimmunoradio/Chemoimmunotherapy
(5FU+thymalin/taktivin, 5-6 cycles+RT 45-50Gy)…..84

Radical Procedures:
 Left Thoracoabdominal Esophagogastrectomies
(Garlock)……………………..……………………..271
 Right Thoracoabdominal Esophagogastrectomies

 (Ivor Lewis)………………….……………………...140

 Combined Esophagogastrectomies with

 Resection of Diaphragm, Pericardium, Lung, Liver,
Pancreas, etc…………..…………..………………...127
 2-Field Lymphadenectomy….……………………..303

 3-Field Lymphadenectomy….……………………..108

Staging:
 T1……62 N0..…170 G1…………116
 T2……99 N1……57 G2…………..98
 T3…..141 N2…..184 G3…………197
 T4…..109 M1……..0
 Adenocarcinoma………..................................216

 Squamos Cell Carcinoma……………………185

 Mix Carcinoma..……………………………….10

 Early Cancer……43

 Invasive Cancer…….368

Survival Rate:
 Alive………………………………………....170 (41%)
 5-Year Survivors…………..……………….102 (24.8%)

 10-Year Survivors…………………………...54 (13%)

 Losses………………………………….……216 (52.6%)

 General Life Span=1632.2±2141.6 days

 For 5-Year Survivors=4491.3±2679.0 days

 For 10-Year Survivors=6228.6±2632.2 days

 For Losses=648.6±387.8 days

 Cumulative 5-Year Survival………………..40.1%

 Cumulative 10-Year Survival………………32.9%

General Esophageal/Cardioesophageal Cancer Patients Survival
after Complete Esophagogastrectomies (Kaplan-Meier) (n=411)

Results of Univariate Analysis of Phase Transition Early—Invasive
Cancer in Prediction of Esophageal/Cardioesophageal Cancer
Patients Survival (n=411)

Results of Univariate Analysis of Phase Transition N0—N1-2 in
Prediction of Esophageal/Cardioesophageal Cancer Patients
Survival (n=411)

Results of Univariate Analysis of Adjuvant Therapy in Prediction
of Esophageal/Cardioesophageal Cancer Patients Survival (n=411)

Results of Univariate Analysis of Tumor Localization in Prediction of
Esophageal/Cardioesophageal Cancer Patients Survival (n=411)

Results of Univariate Analysis of Tumor Hystology in Prediction of

Results of Univariate Analysis of Tumor Growth in Prediction of

Results of Discriminant
Fanction Analysis in
Prediction of
Esophageal/Cardioesophageal
Cancer Patients Survival after
Surgery (n=318)

Results of Multi-Factor Clustering
of Clinicopathological Data in
Prediction of
Complete Esophagectomies (n=318)

Results of Cox Regression Modeling in
Prediction of
Esophageal/Cardioesophageal Cancer
Patients Survival after Surgery (n=411)

Results of Neural Networks Computing
in Prediction of
Patients Survival after Complete
Esophagogastrectomies (n=318)

Results of Bootstrap Simulation in
Prediction of
Complete Esophagectomies
(n=318)

Holling-Tenner Models of
Cell Population and Cytotoxic Cell Population Dynamics

Results of Kohonen Self-Organizing Neural
Networks Computing in Prediction of
Esophageal/Cardioesophageal Cancer Patients
Survival after Complete Esophagogastrectomies (n=318)

Cancer Dynamics

Results of Structurul Equation Modeling
in Prediction of
Esophageal/Cardioesophageal Cancer Patients Survival after
Esophagectomies, n=318

Conclusions:
 Optimal management strategies for esophageal and
cardioesophageal cancer patients are:
 1) screening and early detection;

 2) availability of experienced thoracoabdominal
surgeons because of complexity of radical procedures;
 3) aggressive en block surgery and adequate lymph node
dissection for completeness;
 4) high-precision prediction;

 5) adjuvant treatment for esophageal and
cardioesophageal cancer patients with unfavorable
prognosis.

Address:
Oleg Kshivets, M.D., Ph.D.
Consultant Thoracic, Abdominal,
General Surgeon & Surgical
Oncologist

 e-mail: okshivets@yahoo.com
 skype: okshivets
 http: //www.ctsnet.org/home/okshivets

Kshivets sso2013

More Related Content

What's hot (20)

Similar to Kshivets sso2013 (20)

More from Oleg Kshivets (19)

Kshivets sso2013